Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael R Loken

Showing results (51-60 of 93) with videos related to

Pageof 10
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 26, 2006
Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantationOlga Sala-Torra, Colleen Hanna, Michael R Loken, et al.
Cytometry. Part B, Clinical Cytometry|November 13, 2021
Integrated analysis of genotype and phenotype reveals clonal evolution and cytogenetically driven disruption of myeloid cell maturation in myelodysplastic syndromesJevon A Cutler, Haley R Pugsley, Richard Bennington, et al.
Blood|August 23, 2014
NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG reportFabiana Ostronoff, Megan Othus, Robert B Gerbing, et al.
Pediatric Blood & Cancer|August 12, 2016
miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology GroupRanjani Ramamurthy, Maya Hughes, Valerie Morris, et al.
Blood Cancer Journal|May 23, 2019
ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 TrialRoya Rafiee, Lata Chauhan, Todd A Alonzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2010
High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology groupRoland B Walter, Todd A Alonzo, Robert B Gerbing, et al.
Blood Advances|September 23, 2022
Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1-antibody-drug conjugateThao Tang, Quy Le, Sommer Castro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2017
Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology GroupKatherine Tarlock, Todd A Alonzo, Michael R Loken, et al.
Haematologica|September 9, 2017
Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531Andrew P Voigt, Lisa Eidenschink Brodersen, Todd A Alonzo, et al.
Blood Advances|August 19, 2022
Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemiaDanielle C Kirkey, Anisha M Loeb, Sommer Castro, et al.
Pageof 10

Showing results (51-60 of 93) with videos related to

Sort By:
Pageof 10
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 26, 2006
Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantationOlga Sala-Torra, Colleen Hanna, Michael R Loken, et al.
Cytometry. Part B, Clinical Cytometry|November 13, 2021
Integrated analysis of genotype and phenotype reveals clonal evolution and cytogenetically driven disruption of myeloid cell maturation in myelodysplastic syndromesJevon A Cutler, Haley R Pugsley, Richard Bennington, et al.
Blood|August 23, 2014
NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG reportFabiana Ostronoff, Megan Othus, Robert B Gerbing, et al.
Pediatric Blood & Cancer|August 12, 2016
miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology GroupRanjani Ramamurthy, Maya Hughes, Valerie Morris, et al.
Blood Cancer Journal|May 23, 2019
ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 TrialRoya Rafiee, Lata Chauhan, Todd A Alonzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2010
High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology groupRoland B Walter, Todd A Alonzo, Robert B Gerbing, et al.
Blood Advances|September 23, 2022
Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1-antibody-drug conjugateThao Tang, Quy Le, Sommer Castro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2017
Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology GroupKatherine Tarlock, Todd A Alonzo, Michael R Loken, et al.
Haematologica|September 9, 2017
Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531Andrew P Voigt, Lisa Eidenschink Brodersen, Todd A Alonzo, et al.
Blood Advances|August 19, 2022
Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemiaDanielle C Kirkey, Anisha M Loeb, Sommer Castro, et al.
Pageof 10